| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200-1/1000 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200-1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | MDS; KIAA1546 |
| Entrez GeneID | 54790 |
| clone | 5H8C7 |
| WB Predicted band size | 223.8kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human TET2 expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于TET2抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**: *TET2 mutations in myelodysplastic syndromes and acute myeloid leukemia*
**作者**: Ko M, Huang Y, Jankowska AM, et al.
**摘要**: 该研究发表于《Nature》，揭示了TET2基因突变在骨髓增生异常综合征(MDS)和急性髓系白血病(AML)中的关键作用。研究中通过TET2抗体进行Western blot和免疫组化，验证了突变导致的TET2蛋白表达水平下降，并证明其与DNA异常高甲基化及造血分化障碍相关。
---
2. **文献名称**: *TET2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation*
**作者**: Quivoron C, Couronné L, Della Valle V, et al.
**摘要**: 该论文(《Cancer Cell》)利用TET2敲除小鼠模型，结合TET2抗体的免疫沉淀和染色质分析，证明TET2缺失会增强造血干细胞的自我更新能力并促进髓系恶性肿瘤发生。研究通过抗体检测TET2蛋白的亚细胞定位，揭示了其在表观遗传调控中的动态作用。
---
3. **文献名称**: *TET2 regulates the anti-leukemic efficacy of 5-azacitidine in acute myeloid leukemia*
**作者**: Cimmino L, Dolgalev I, Wang Y, et al.
**摘要**: 该研究(《Blood》)探讨了TET2表达水平对AML患者化疗响应的影响。通过TET2抗体的流式细胞术和免疫印迹分析，作者发现低TET2蛋白水平与5-氮杂胞苷治疗敏感性降低相关，提示TET2可作为表观遗传治疗的生物标志物。
---
**备注**：以上文献均涉及TET2抗体的实验应用(如蛋白表达检测、功能研究)，但若需具体抗体开发或验证的研究，建议补充检索关键词“TET2 antibody validation”或“TET2 epitope mapping”。
TET2 (Tet methylcytosine dioxygenase 2) is an epigenetic regulator belonging to the TET family of enzymes that catalyze the oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), a key step in DNA demethylation. This process modulates gene expression and maintains genomic stability. TET2 mutations are frequently observed in hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), making it a critical biomarker and therapeutic target in cancer research.
TET2 antibodies are essential tools for studying its expression, localization, and function. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP-seq) to investigate TET2's role in epigenetic regulation and disease. Commercially available TET2 antibodies are typically raised against specific epitopes, such as the C-terminal or N-terminal regions, and vary in host species (e.g., rabbit, mouse) and clonality (monoclonal/polyclonal). Validation includes testing in TET2-knockout cell lines to confirm specificity.
Challenges in TET2 antibody use include cross-reactivity with other TET family members (TET1. TET3) and variability in performance across experimental conditions. Researchers must carefully select and validate antibodies based on their specific applications. Overall, TET2 antibodies are indispensable for advancing our understanding of epigenetics, hematopoiesis, and cancer biology.
×
